

ASX Release

Oventus receives US patent application approval for its Airway Technology incorporated into O₂Vent™ oral devices

Key points:

- **US patent application approval for ‘Oventus Airway Technology’ incorporated into O₂Vent™ oral devices**
- **Combined with prior approvals, provides coverage for ‘Oventus Airway Technology’ targeted for product roll out across key markets; Australia, Europe and US**
- **This patent family is the platform for the remaining Oventus patent families – currently 8 in total**

Brisbane, Australia 7 June 2018: Oventus Medical Ltd (ASX: OVN) is pleased to advise that it has received a Notice of Allowance from the US Patent and Trade Mark Office for application USSN14/118,416 relating to our breathing assistance apparatus including an integrated airway.

The integrated airway or ‘Oventus Airway Technology’ is incorporated into our O₂Vent™ oral devices for the treatment of sleep apnoea and snoring.

Oventus also has corresponding patent protection in place for its technology from the Australian Patent Office in the Australian market, and has also recently received a Notice of Allowance from the European Patent Office for Europe.

Oventus CEO, Neil Anderson commented, “This initial patent is key to our whole patent strategy and protects the fundamental invention of the use of an airway from the front to the back of the mouth. It is the reason why our appliances work so well compared to existing mandibular advancement devices. It is also the platform for which our additional families are based on. Consequently the patent’s allowance in the US – a key market for us, is a significant milestone for the company.”

About the Oventus O₂Vent™ airway technology

The Oventus O₂Vent™ is an oral appliance device which brings the lower jaw forward (a process commonly referred to as mandibular advancement) and incorporates an opening to the oral cavity to allow breathing through the device airway, bypassing obstructions of the nose soft palate, stabilising the tongue base tongue and reducing airway collapsibility during sleep.

Further information can be found on our website: <http://oventus.com.au/how-it-works/>.

—ENDS—



BETTER SLEEP, BETTER HEALTH and a BETTER LIFE

For more information, please contact:

Mr Neil Anderson, Managing Director and CEO: M: 0403 003 475

Jane Lowe, IR Department: M: 0411 117 774 or jane.lowe@irdepartment.com.au

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nCPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O₂Vent™ is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*